Wegovy® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity, to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight and that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.
Wegovy®, along with a reduced calorie diet and increased physical activity, is used to help children aged 12 years and older with obesity to lose excess body weight and keep it off.
Limited one
time offer
Cardiovascular (CV) Risk Reduction
Along with a reduced calorie diet and increased physical activity
In adults with known heart disease and with either obesity or overweight
Wegovy® helped lower the risk of major CV events like death, heart attack, or stroke
A clinical study looked at the effects of Wegovy® on CV risk
The effect of Wegovy® 2.4 mg once weekly on the risk of major CV events like death, heart attack, or stroke was studied in adults with known heart disease and either obesity or overweight compared with those on placebo (an inactive injection). On average, adults were in the trial for 3.5 years (41.8 months).
All study participants also received standard of care for their heart disease as recommended by their health care professional. This included medications for managing CV risk factors like high blood pressure or high cholesterol, as well as individualized healthy lifestyle counseling (including diet and physical activity).
A clinical study looked at the effects of Wegovy® on CV risk
The effect of Wegovy® 2.4 mg once weekly on the risk of major CV events like death, heart attack, or stroke was studied in adults with known heart disease and either obesity or overweight compared with those on placebo (an inactive injection). On average, adults were in the trial for 3.5 years (41.8 months).
All study participants also received standard of care for their heart disease as recommended by their health care professional. This included medications for managing CV risk factors like high blood pressure or high cholesterol, as well as individualized healthy lifestyle counseling (including diet and physical activity).
Wegovy® is the first weight-management medicine that is FDA approved to lower the risk of major CV events.
CV events include death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
Take a closer look at the impact of obesity
 |
What I want people to realize about obesity is that it’s not a lack of willpower. It’s a chronic disease.—Lisa, taking Wegovy® since 2021* *Real Wegovy® patient. Lisa is compensated by Novo Nordisk. |
It took a long time, but in 2013, the American Medical Association finally recognized obesity as a disease. We now know that multiple factors, not just lifestyle, can impact a person’s weight. Get a better understanding of obesity and what causes it.
See what else is possible with Wegovy®
Learn about the medical study results around weight loss and benefits beyond the scale.
Next:
Questions?
Need assistance or information?
Call the Wegovy® Navigation Line at 1-833-4-WEGOVY (1-833-493-4689) between 9:00 AM and 6:00 PM ET, Monday–Friday.
